Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis

Rheumatology

Volumn 38, Issue 1, 1999, Pages 34-42

  Cunnane, G ^a   FitzGerald, O ^a   Hummel, K M ^b   Gay, R E ^b   Gay, S ^b   Bresnihan, B ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cathepsin B; Cathepsin L; Collagenase; Early arthritis; In situ hybridization; Synovial membrane

Indexed keywords

CATHEPSIN B; CATHEPSIN L; COLLAGENASE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CATHEPSIN B; CATHEPSINS; COLLAGENASES; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION; GOUT; HUMANS; IN SITU HYBRIDIZATION; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; RNA, MESSENGER; SPONDYLITIS, ANKYLOSING; SYNOVIAL MEMBRANE;

EID: 0032710355     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.1.34     Document Type: Article

References (48)

1. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52(suppl. 1):39-47.
2. Werb Z. Proteases and matrix degradation. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology, 3rd edn. Philadelphia: WB Saunders, 1989:300-21.
3. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994;37:1115-26.
4. Muller-Ladner U, Gay RE, Gay S. Cysteine proteinases in arthritis and inflammation. In: McKerrow JH, James MNG, eds. Perspectives in drug discovery and design. Leiden: ESCoM, 1996:87-97.
5. Woolley DE, Evanson JM. Collagenase in normal and pathological connective tissues. New York: John Wiley and Sons, 1980.
6. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
7. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP) and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993;36:372-9.
8. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
9. McCachren SS. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991;34:1085-93.
10. Brinckerhoff CE. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum 1991;34:1073-5.
11. Zafarullah M, Pelletier JP, Cloutier JM, Martel-Pelletier J. Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. J Rheumatol 1993;20:693-7.
12. Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A, Nakanishi I et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992;66:680-90.
13. Wooley DE, Crossley MJ, Evanson JM. Collagenase at sites of cartilage erosion in the rheumatoid joint. Arthritis Rheum 1977;20:1231-9.
14. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781-90.
15. Wang AZ, Wang JC, Fisher GW, Diamond HS. Interleukin-1β-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. Arthritis Rheum 1997;40:1298-307.
16. Maciewicz RA, Wotton SF. Degradation of cartilage matrix components by the cysteine proteases, cathepsin B and L. Biomed Biochim Acta 1991;50:561-4.
17. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Nilson-Hamilton M, Hamilton RT et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/l mice and patients with rheumatoid arthritis. Matrix 1990;10:349-61.
18. Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 1991;34:1444-51.
19. Iwata Y, Mort JS, Tateishi H, Lee ER. Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis Rheum 1997;40:499-509.
20. Reddy VY, Zhang QY, Weiss SJ. Pericellular mobilization of the tissue destructive cysteine proteinases, cathepsins B, L and S, by human monocyte-derived macrophages. Proc Natl Acad Sci USA 1995;92:3849-53.
21. Meijers MH, Koopdonk-Kool J, Meacock SC, Van Noorden CJ, Bunning RA, Billingham ME. Cysteine proteinase activity in the development of arthritis in an adjuvant model of the rat. Agents Actions 1993;39:C219-21.
22. Keyszer GM, Heer AH, Kriegsmann J, Geiler T, Trabandt A, Keysser M et al. Comparative analysis of cathepsin L, cathepsin D and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum 1995;38:976-84.
23. Esser RE, Watts LM, Angelo RA, Thornburg LP, Prior JJ, Palmer JT. The effects of fluoromethyl ketone inhibitors of cathepsin B on adjuvant induced arthritis. J Rheumatol 1993;20:1176-83.
24. 2F. J Rheumatol 1988;15:1525-35.
25. Buttle DJ, Handley CJ, Ilic MZ, Saklatvala J, Murata M, Barrett AJ. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum 1993;36:1709-17.
26. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
27. Beltran J, Caudill JL, Herman LA, Kantor SM, Hudson PN, Noto AM et al. Rheumatoid arthritis. MRI manifestations. Radiology 1987;165:153-7.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
29. Moll JMH, Wright V. New York clinical criteria for ankylosing spondylitis. a statistical evaluation. Ann Rheum Dis 1973;32:354-63.
30. Veale D, Rogers S, FitzGerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994; 33:133-8.
31. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
32. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991;34:1094-105.
33. Mulherin D, FitzGerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115-24.
34. Brennan FM, Field M, Chu QQ, Feldman M, Maini RN. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991;30:76-80.
35. Cunnane G, Madigan A, Cassidy N, FitzGerald O, Bresnihan B. Treatment of rheumatoid arthritis with interleukin-1 receptor antagonist (IL-1ra): immunohistologic evidence of interleukin-1-induced manifestions of synovitis. Br J Rheumatol 1998;37(suppl. 1):6.
36. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domijan Z, Emery P et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-204.
37. Codorean E, Gabrielescu E. Cytochemical investigation of cathepsin B in rheumatoid synovial membrane and fluid. Morphol Embryol 1985;31:269-74.
38. Tetlow LC, Woolley DE. Mast cells, cytokines and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 1995;54:896-903.
39. Firestein GS, Paine MM, Boyle DL. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum 1994;37:193-200.
40. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. J Biol Chem 1986;261:2814-8.
41. Trabandt A, Gay RE, Gay S. Oncogene activation in rheumatoid synovium. APMIS 1992;100:861-75.
42. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, FitzGerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
43. Black R, Kronheim S, Sleath P, Greenstreet T, Duke Virca G, March C et al. The proteolytic activation of interleukin-1beta. Agents Actions 1991;35(suppl.):85-9.
44. Mort JS, Buttle DJ. Cathepsin B. Int J Biochem Cell Biol 1997;29:715-20.
45. Matsunaga Y, Saibara T, Kido H, Katunuma N. Participation of cathepsin B in processing of antigen presentation to MHC class 11. FEBS Lett 1993;324:325-30.
46. Zvaifler NJ, Boyle D, Firestein GS. Early synovitis - synoviocytes and mononuclear cells. Semin Arthritis Rheum 1994;23:11-6.
47. Ostergaard M, Stoltenberg M, Gideon P, Sorensen K, Henriksen O, Lorenzen I. Changes in synovial membrane and joint effusion volumes after intraarticular methylprednisolone. Quantitative assessment of inflammatory and destructive changes in arthritis by MRI. J Rheumatol 1996;23:1151-61.
48. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Jensen CH, Lorenzen IB. Magnetic resonance imaging-determined synovial membrane and joint effusion volumes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1997;40:1856-67.